"In vitro" studies have shown comparable resistance profile to that of the other next generation NNRTIs.In November 2009 the candidate entered phase II clinical trials, but the trial and all further development was halted when 5 of 35 subjects receiving fosdevirine experienced delayed-onset seizures.